Novel Antimicrobial Strategies


Active/Enrolling:

None at this time; please check back soon.

Closed to Enrollment:

None at this time; please check back soon.

Pending:

ERASE

  • Principal Investigator: Gary Wang, MD, PhD
  • Link TBA
  • ERASE is a Phase 2b, open-label, multiple-ascending dose study aiming to evaluate the safety, tolerability, efficacy, and pharmacokinetics of LSVT-1701 as an adjunct to standard of care antibiotic treatment in hospitalized patients with complicated methicillin-sensitive and -resistant S. aureus bacteremia (SAB), including left- and right-sided infective endocarditis. Secondary objectives of this study are to monitor the clinical and microbiological effects of the investigational product.
  • Contact: Kyle Barbera, kyle.barbera@medicine.ufl.edu, 352-273-8891

diSArm

  • Principal Investigator: Gary Wang, MD, PhD
  • https://www.clinicaltrials.gov/ct2/show/NCT05184764
  • Staphylococcus aureus is one of the most commonly identified pathogens in hospitalized patients with bacteremia, a bacterial infection of the bloodstream. The diSArm study seeks to evaluate the safety, tolerability, and efficacy of an intravenous agent, AP-SA02, in treating S. aureus bacteremia. This is a Phase 1b/2a, randomized, double-blinded study examining multiple doses of AP-SA02 as an adjunct to the best available therapy (BAT). Phase 1b examines multiple ascending IV doses of AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in patients with S. aureus bacteremia. Phase 2a will examine multiple doses of AP-SA02 or placebo as an adjunct to BAT compared to BAT alone in patients with complicated S. aureus bacteremia.
  • Contact: Kyle Barbera, kyle.barbera@medicine.ufl.edu, 352-273-8891

Completed:

None at this time; please check back soon.